Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights

Rhea-AI Summary

Hemogenyx Pharmaceuticals plc announces that the total issued share capital of the Company consists of 1,153,065,988 ordinary shares. None of the shares are held in treasury. The total number of voting rights in the Company is 1,153,065,988.

LONDON, UK / ACCESSWIRE / October 31, 2023 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 31 October 2023 consists of 1,153,065,988 ordinary shares of 1 pence each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 1,153,065,988.

The figure of 1,153,065,988 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director	peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View source version on accesswire.com:
https://www.accesswire.com/797909/hemogenyx-pharmaceuticals-plc-announces-total-voting-rights

FAQ

What is the total issued share capital of Hemogenyx Pharmaceuticals plc?

The total issued share capital of Hemogenyx Pharmaceuticals plc is 1,153,065,988 ordinary shares.

Are any shares held in treasury?

No, none of the shares are held in treasury.

What is the total number of voting rights in the Company?

The total number of voting rights in Hemogenyx Pharmaceuticals plc is 1,153,065,988.

Who can use the figure of 1,153,065,988 ordinary shares?

Shareholders of Hemogenyx Pharmaceuticals plc can use the figure of 1,153,065,988 ordinary shares for calculations related to their investment or a change in their interest in the share capital of the Company.

Who is the Chief Executive Officer & Co-Founder of Hemogenyx Pharmaceuticals plc?

The Chief Executive Officer & Co-Founder of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler.